肾上腺癌唯一的克星解腺瘤片

The structure of adenoma tablets is similar to that of the insecticides DDT and DDD, which can cause atrophy and necrosis of the adrenal cortex. After administration, the levels of adrenocortical hormones and their metabolites in the body can be rapidly reduced, and it can be used to treat Kewpie syndrome caused by adrenal tumors or adrenal hyperplasia. Today we will learn more about the only nemesis of adrenal cancer, Adenoma Relief Tablets.

Adenoma Relief Tablet is a specific drug used for the treatment of inoperable, functional and non-functional adrenocortical cancer, adrenal hyperplasia and tumor-induced hypercortisolism. The objective effective rate of adenoma-resolving tablets is 34% to 61%, and the median remission period is 6 to 7 months. For functional adrenocortical cancer, it can alleviate the symptoms of cortical hyperfunction, shrink tumors, and prolong life.

Most studies show that the median survival time for patients with end-stage adrenocortical carcinoma (ACC) is approximately 12 months. Adenomatase is the only drug approved for use in patients with end-stage ACC. Despite the lack of prospective controlled studies, adenolytic tablets were approved in the United States in 1970 and in Europe in 2004 for the treatment of patients with end-stage ACC. Most of the data come from a series of retrospective studies, which showed a maximum response rate of 24% for adenoma tablets in the treatment of end-stage ACC.

Foreign studies have also found that Adenoma-Reducing Tablets can inhibit 5α-reductase and androgen activity, so active androgen replacement therapy can be carried out based on the patient's clinical manifestations and laboratory test results; Adenoma-Resolving Tablets can also increase the level of binding proteins in the blood, and thyroid hormone replacement therapy should be considered based on the free thyroxine level and the patient's clinical symptoms.

A clinical study showed that the total effective rate of mitotane combined with cisplatin reached 48.6%, the total tumor progression-free time was 9.1 months, and the overall survival time was 28.5 months. Among patients who were effective in this regimen, the tumor progression-free time reached 18.2 months, and the overall survival time was nearly 4 years. (47.7 months). Among them, 19.4% of patients had a progression-free time of more than 2 years, and nearly 10% of patients had a progression-free time of more than 5 years. 48.6% of patients had an overall survival time of more than 2 years, and 14% of patients had an overall survival time of more than 5 years. The treatment effect is significantly improved compared with other regimens.

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.